Skip to main content

Advertisement

SpringerLink
Log in

Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration

  • Clinical Investigation
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Background

The purpose of the study is to report data on short-term safety of intravitreal bevacizumab treatment and its effect on visual function, central retinal thickness, and angiographical changes of occult choroidal neovascularization due to age-related macular degeneration.

Methods

A consecutive interventional case series of 30 patients with active subfoveal occult choroidal neovascularization secondary to age-related macular degeneration was followed after one intravitreal injection of 1.25 mg bevacizumab at baseline and subsequent injections following standardized criteria. At baseline and follow-up visits patients had visual acuity assessment, intraocular pressure measurement, fluorescein angiography, and optical coherence tomography imaging.

Results

No serious ocular or systemic adverse events were identified. A significant increase of intraocular pressure or signs of retinal toxicity or endophthalmitis were not detected in any patient. Optical coherence tomography revealed significant decrease (p < 0.001) in central retinal thickness after 1 week, 4 weeks, and 12 weeks, respectively. Fluorescein leakage decreased within 1 week and improvement was maintained at week 12 in the majority of patients. Visual acuity improved or remained stable in 29 of 30 patients; improvement of 3 or more lines was seen in 14 of 30 patients; one patients showed improvement of 6 lines. No patient had severe vision loss of 6 lines or more; moderate vision loss of 3 lines was seen in one patient. Re-injections of bevacizumab according to standard criteria were performed one to two times during the follow-up period of 12 weeks with a re-injection interval of 4 to 18 weeks (median 8 weeks).

Conclusions

Short-term results suggest that intravitreal injection of bevacizumab is well tolerated and for the majority of patients with occult choroidal neovascularization in AMD results in improvement of visual acuity, decrease in central retina thickness, and reduction of angiographic leakage of the lesion. Bevacizumab as intravitreal treatment may provide a novel therapeutic option for selected patients with exudative AMD. Randomized prospective multicenter trials seem justified to further evaluate long term effects and impact of intravitreal bevacizumab on different subtypes of AMD compared to established therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Adamis AP, Shima DT (2005) The role of vascular endothelial growth factor in ocular health and disease. Retina 25:111–118

    Article  PubMed  Google Scholar 

  2. Avery RL, Pieramici DJ, Rabena MD et al (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related degeneration. Ophthalmology 113:363–372

    Article  PubMed  Google Scholar 

  3. Axel-Sieger R, Ehrlich R, Rosenblatt I, Kramer M, Priel E, Yassur Y, Weinberger D (2004) Photodynamic therapy for occult choroidal Neovascularization with pigment epithelium detachment in age-related macular degeneration. Arch Ophthalmol 122:453–459

    Article  Google Scholar 

  4. Eyetech Study Group (2002) Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 22:143–152

    Article  Google Scholar 

  5. Eyetech Study Group (2003) Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology 110:979–986

    Article  Google Scholar 

  6. Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581–611

    Article  PubMed  CAS  Google Scholar 

  7. Ferris FL III, Fine SL, Hyman L (1984) Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 102:1640–1642

    PubMed  Google Scholar 

  8. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186

    Article  PubMed  CAS  Google Scholar 

  9. Gragoudas ES, Adamis AP, Cunningham ET Jr et al (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351:2805–2816

    Article  PubMed  CAS  Google Scholar 

  10. Hurwitz H, Fehrenbacher J, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342

    Article  PubMed  CAS  Google Scholar 

  11. Jackson TL, Antcliff RJ, Hillenkamp J, Marshall J (2003) Human retinal molecular weight exclusion limit and estimate of species variation. Invest Ophthalmol Vis Sci 44:2141–2146

    Article  PubMed  Google Scholar 

  12. Jaissle GB, Szurman P, Bartz-Schmidt KU; German Retina Society; German Society of Ophthalmology; German Professional Association of Ophthalmologists (2005) Recommendation for the implementation of intravitreal injections–statement of the German Retina Society, the German Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmologists (BVA). Klin Monatsbl Augenheilkd 222:390–395

    Article  PubMed  CAS  Google Scholar 

  13. Konerding MA (2004) Ocular angiogenesis: translating preclinical indications to successful clinincal development. Expert Opin Ther Targets 8:255–258

    Article  PubMed  CAS  Google Scholar 

  14. Krystolik MG, Afshari MA, Adamis AP et al (2002) Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 120:338–346

    Google Scholar 

  15. Kvanta A, Algvere PV, Berglin L, Seregard S (1996) Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 37:1929–1934

    PubMed  CAS  Google Scholar 

  16. Lafaut BA, Bartz-Schmidt KU, Vanden Broecke C, Aisenbrey S, De Laey JJ, Heimann K (2000) Clinicopathological correlation in exudative age related macular degeneration: histological differentiation between classic and occult choroidal neovascularisation. Br J Ophthalmol 84:239–243

    Article  PubMed  CAS  Google Scholar 

  17. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306–1309

    Article  PubMed  CAS  Google Scholar 

  18. Macular Photocoagulation Study Group (1991) Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized trial. Arch Ophthalmol 109:1220–1241

    Google Scholar 

  19. Manzano RP, Peyman GA, Khan P, Kivilcim M (2006) Testing intravitreal toxicity of Bevacizumab (Avastin). Retina 26:257–261

    Article  PubMed  Google Scholar 

  20. Michels S, Rosenfeld PJ, Puliafito CA et al (2005) Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration - twelve week results of an uncontrolled open-label clinical study. Ophthalmology 112:1035–1047

    Article  PubMed  Google Scholar 

  21. Mordenti J, Cuthbertson RA, Ferrara N et al (1999) Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 27:536–544

    PubMed  CAS  Google Scholar 

  22. Nguyen QD, Shah S, Tatlipinar S et al (2005) Bevacizumab suppresses choroidal neovascularization cased by pathological myopia. Br J Ophthalmol 89:1368–1370

    Article  PubMed  CAS  Google Scholar 

  23. Pauleikhoff D (2005) Neovascular age-related macular degeneration. Natural history and treatment outcomes. Retina 25:1065–1084

    Article  PubMed  Google Scholar 

  24. Reichel E (2005) Intravitreal bevacizumab for choroidal neovascularization and cystoid macular edema: a cost-effective treatment? Ophthalmic Surg Lasers Imaging 36:270–271

    PubMed  Google Scholar 

  25. Rosenfeld PJ, Mosfeghi AA, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36:331–335

    PubMed  Google Scholar 

  26. Rosenfeld PJ, Schwartz SD, Blumenkranz MS et al (2005) Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 112:1048–1053

    Article  PubMed  Google Scholar 

  27. Saishin Y, Saichin Y, Tkahashi K et al (2003) VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol 195:241–248

    Article  PubMed  CAS  Google Scholar 

  28. Shahar J, Avery RL, Heilweil G, Barak A, Zemel E, Lewis GP, Johnson PT, Fisher SK, Perlman I, Loewenstein A (2006) Electrophysiological and retinal penetration studies following intravitreal injection of Bevacizumab (Avastin). Retina 26:262–269

    Article  PubMed  Google Scholar 

  29. Spaide RF, Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA, Sorenson J, Slakter J, Fisher YL, Cooney MJ (2006) Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26:383–390

    Article  PubMed  Google Scholar 

  30. Treatment of age-related macular degeneration with photodynamic therapy study group (1999) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Arch Ophthalmol 117:1329–1345

    Google Scholar 

  31. Treatment of age-related macular degeneration with photodynamic therapy study group, Verteporfin in Photodynamic Therapy Study Group (2003) Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment-TAP and VIP report No. 2. Arch Ophthalmol 121:1253–1268

    Article  Google Scholar 

  32. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group (2005) Enhanced efficacy associated with early treatment of neovascular macular degeneration with pegaptanib sodium: an exploratory analysis. Retina 25:815–827

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center of Ophthalmology, University of Tuebingen, Schleichstrasse 12, 72076, Tuebingen, Germany

    S. Aisenbrey, F. Ziemssen, M. Völker, F. Gelisken, P. Szurman, G. Jaissle, S. Grisanti & K. U. Bartz-Schmidt

Authors
  1. S. Aisenbrey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Ziemssen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Völker
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. Gelisken
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. Szurman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Jaissle
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S. Grisanti
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. K. U. Bartz-Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Aisenbrey.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aisenbrey, S., Ziemssen, F., Völker, M. et al. Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 245, 941–948 (2006). https://doi.org/10.1007/s00417-006-0471-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-006-0471-7

Keywords

Search

Navigation